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1  introDuction
The New Zealand Law Foundation-sponsored Human Genome Research Project 
is a multi-disciplinary and international project. It examines issues raised by 
developments and advances in human genome-based technologies and knowledge; 
the responsible use of such technologies and knowledge to improve the health and 
well-being of New Zealanders; and inter-relationships between genetic knowledge, 
medical sciences, clinical practices, the humanities, government regulation and 
policies and the law. In the second year of the project, part of the research work 
involves looking into new and emerging initiatives and applications in genetics for 
newborns. The current New Zealand newborn metabolic screening programme is 
chosen as the starting point for a number of reasons. 
Firstly, the newborn screening programme provides a useful case study for examining 
the relationship between advances in knowledge and technology that stem from the 
sequencing of the human genome and the need or desirability for public policy to 
catch up.1 As an intervention to improve population health, the programme has very 
wide coverage in terms of participation numbers and has been running for a long 
time.2 Ongoing experiences with the programme provide a rich context for analysing 
emerging ethical, regulatory and legal questions raised by changing expectations, 
new frameworks and law reform, and also for investigating future policy options.
Secondly, the current newborn screening programme measures changes in the levels 
of blood compounds, for example enzymes, amino acids, hormones and metabolites, 
to detect the possibility of early onset genetic disorders. In effect, the programme 
involves an indirect method of genetic screening. Close study of some of the issues 
that emerge will be helpful in terms of thinking ahead about future genetic screening 
programmes.3 Related to this are questions about the changing paradigms that will 
be driven by advances in genome-based knowledge and which will have implications 
for public health.
Thirdly, as part of an examination of relevant new technologies, our attention has 
been drawn to the two novel technologies of tandem mass spectrometry and DNA 
microarray, which are revealing a range of applications in areas that include newborn 
screening. While the former was introduced to the newborn screening programme 
in December 2006, and provides a basis for inferring the presence or absence of the 
genetic metabolic condition in question, emerging knowledge about the latter seems 
to point to exciting potential applications with the ability to test for DNA directly.
Fourthly, the dried blood spots collected on Guthrie cards that are currently stored 
indefinitely represent an inchoate ‘DNA bank’.4 The collection of samples was 
estimated in 2003 to be in the order of 1.9 million5 and to date potentially comprises 
the DNA profile of almost every person in New Zealand born since blood spot 
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samples were taken in the late 1960s or early 1970s. The collection of samples6 has 
been described by a parliamentarian7 as a ‘virtual databank’. With relevant legislative 
proposals having been introduced,8 now seems to be a good time to revisit and clarify 
the justification for, and policies regarding, the retaining of the samples after the 
central aims of the programme have been fulfilled.
Fifthly, it came to the notice of the Project during its early stages that the Government 
of the United Kingdom had referred to the possibility in the long term of screening 
babies at birth as part of the standard postnatal checks, and of producing a 
comprehensive map of their key genetic markers or entire genome that would be 
stored on their electronic patient record.9 The intended purpose of such genetic 
profiling at birth would be for tailoring prevention and treatment regimes to their 
needs throughout their lifetime, using increasingly available knowledge about how 
genes affect risk of disease and response to medicines. It is our view that we should 
be ready to participate in debates about the issues when they start to take shape. It 
is timely to begin looking into future technologies and emerging knowledge, and 
to think ahead about regulatory options relating to the existing newborn screening 
programme around which any such proposal is likely to be based.
Central to the examination of the legal issues relating to newborn screening are 
the findings made by two Commissioners. The first set of findings arose from the 
investigation of the Health and Disability Commissioner into a complaint relating to 
informed consent for neonatal blood tests.10 The second was the result of the inquiry 
of the Privacy Commissioner into the collection, retention, use and release of newborn 
metabolic screening test samples.11
Events surrounding the involvement of both Commissioners had their genesis in 
H v G12 in which an application was made to the Court for the release of a deceased 
baby’s dried blood spot sample card, retained by the newborn screening programme, 
for the purpose of DNA analysis to prove paternity. The baby’s mother opposed the 
application, claiming that it would involve using the sample for a purpose other than 
the original intent for which it had been obtained. Salmon J ordered the release of the 
sample and it was tested. On appeal13 by the baby’s mother, Morris J held that the 
analysis of the sample had been undertaken under an order of the Court and the 
results of the DNA identification were admissible as evidence.
The Court decision of H v G was given in 1999 and the recommendations from the 
Privacy Commissioner were provided in 2003. Since then, there has been a considerable 
number of overseas studies and developments in scientific knowledge; much research 
into parental perceptions; and new policy proposals and State initiatives. In New 
Zealand, although progress appears to have been slow, some movement on a number 
of initiatives is discernible.14
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In our view, the findings of the High Court and the Commissioners taken together 
draw attention to issues about the newborn screening programme that can be 
separately conceptualised in terms of:
1. the collection, use and storage of dried blood spots for fulfilling the aims of the 
newborn screening programme; and
2. the storage and use of dried blood spots for purposes beyond fulfilling the aims 
of the newborn screening programme.
This report will discuss the involvement of parents in terms of ‘participation’ in 
the newborn screening programme and then examine issues relating to (1). Issues 
relating to (2) will be discussed in a separate, subsequent report.
2  ParticiPation in the newBorn screening Programme
A broad view is taken in this report of the involvement of parents and the 
responsibilities of health-care providers with regard to newborn screening within 
the New Zealand legal and ethical framework. The expression ‘participation’ is used 
here to give recognition to an increase in shared decision-making between health 
professionals and parents in order to protect and promote the interest of newborns, 
and to emphasise the importance of enlisting the support of parents who are invited 
to take part in the programme so that blood samples from their newborns can be 
obtained for screening. 
Standard approaches adopted when analysing or framing medico-legal issues typically 
begin with or inevitably converge on the issue of informed consent. The Privacy 
Commissioner and Health and Disability Commissioner clearly communicated the 
need for informed consent. This is reflected in the language used in their reports and 
in the formulation of their findings and recommendations. The approach taken in 
this report reinforces that of the commissioners by emphasising the importance of 
informed consent for voluntary participation in newborn screening. 
Examination of the issues makes more explicit the context and the supporting 
elements in which informed consent is to be meaningfully sought by health-
care providers and granted by parents or legal guardians in the circumstance of 
participation in a screening programme. The analysis is grounded in the rights-based 
Code of Health and Disability Services Consumers’ Rights 1996 (‘Code of Rights’), 
and takes into account both the public health paradigm that justifies population-
based interventions for securing overall beneficial outcomes and the striking aspects 
of dealing with genetic risks in families. 
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Screening has to be distinguished from personal clinical services. Clinical services 
are provided to individuals who seek medical help because they suspect or have 
symptoms of a problem. In contrast, screening is offered to a defined population, 
such as women in a specific age group for breast or cervical screening, or, in the 
case of the newborn metabolic screening programme, all newborns. Parents15 are 
approached to identify individuals who could be helped by further tests or treatment 
to reduce the risk of a disease or its complications.16
Underpinning the nature and scope of a population-based intervention such as the 
newborn screening programme is the framing of regulatory and policy mechanisms 
to give weight to maximising participation from members of the target population. 
However, while measures with legal force used in traditional public health contexts 
were prescriptive in form and, in effect, compelled participation, they are now written 
in enabling terms based on patient or consumer rights and actively promote informed 
choice and the obtaining of consent. This shift in public health is consonant with 
approaches in the context of genetic medicine, extending beyond prevention, treatment 
and care to incorporate future reproductive decisions relevant to the family.
   the coDe oF rights anD the newBorn screening   
 Programme
Informed consent in the New Zealand health-care context is formally and explicitly 
recognised in statute17 and provides the central focus for patient and consumer rights 
and advocacy. Informed consent is specifically defined to mean consent freely given 
to any health-care procedure by or on behalf of a health consumer and obtained 
according to the Code of Health and Disability Consumers’ Rights (‘the Code’).18 
The Code systematically sets out the rights of consumers and obligations placed 
on providers of health and disability services. Three elements are vital to successful 
participation in the newborn screening programme: communication between the 
health provider or professional and the consumer; availability of adequate information 
for the consumer; and the opportunity for the consumer to exercise informed choice 
and consent. These are encapsulated in rights 5, 6 and 7 of the Code respectively. 
Rights 5 and 6 are important, in that they represent the two key steps prior to the 
exercising of choice and consent set out in right 7.
.1  right : right to effective communication
Right 5(1) of the Code provides that every consumer has the right to effective 
communication in a form, language and manner that enables the consumer to 
understand the information provided.19 Right 5(2) provides that every consumer 
has the right to an environment that enables both the consumer and provider to 
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communicate openly, honestly and effectively. Right 5, in essence, requires a mode 
of communication that enables understanding. The matters raised here are different 
from the question of what particular information is given, which is more appropriately 
discussed later under right 6.
3.1.1  Timing and distribution of leaflets to parents
The references to communication in right 5, particularly that which relates to the 
appropriate manner and environment for communication to take place to enable 
understanding, raise questions about the opportunities available for consumers to ask 
questions, digest responses to questions and information and familiarise themselves 
or be acquainted with the facts. Crucial to these would be issues of timing, including 
those times at which opportunities are provided to facilitate this process; the length 
of time allocated for each of those opportunities; and the length time separating the 
taking of the baby’s blood sample from the parents’ considered decision regarding 
participation.20 Empirical studies or quality assurance reports regarding these issues 
are not presently available for newborn screening in New Zealand. 
In the complaint investigated by the Health and Disability Commissioner, the right to 
effective communication was not an issue. This was because the two relevant health 
professionals had not, for separate reasons, sought informed consent.21 Of relevance 
to the issue of effective communication is the Privacy Commissioner’s informal 
survey of eleven maternity hospitals relating to screening information contained in 
a leaflet Your Newborn Baby’s Blood Test that is produced by the National Testing 
Centre. The Privacy Commissioner said the presentation of the leaflet to the mother 
‘at least provides a natural opportunity for the lead maternity carer (‘LMC’) to explain 
those matters in which the leaflet is inadequate in its explanation’. However, the 
Commissioner found that ‘even the leaflet distribution appears to be unreliable’.22
Timing is a key factor in the distribution of the leaflets in order to initiate meaningful 
discussion about the conducting of the screening test. It is difficult to regard the 
circumstances following childbirth as providing the appropriate conditions and 
environment for this to happen. Elkin and Jones, who have also made this point, 
noted the findings of a study that found that when women were asked for consent just 
before the test, they tended to feel ‘psychologically committed’ to the test and so were 
less receptive to disclosed information.23 Researchers for the STAR-G Project in the 
United States learned from their participants that the ideal time to educate parents 
about newborn screening is during the third trimester of the prenatal period.24 
Also, recently published findings from research involving focus groups comprising 
parents, providers and experts reported that all participants thought that parents 
should receive information in concise, easy-to-read brochures preferably in the third 
trimester of pregnancy.25
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The draft Interim Standards for the Newborn Metabolic Screening is not currently 
publicly available.26 A supplementary report by the Victorian Privacy Commissioner 
to the final report by the Victorian Newborn Screening Review Committee for 
the Minister of Health in August 2006 recommended that ‘information should 
be conveyed in a manner that allows time for reflection and consideration of the 
implications … [and] should be provided early during prenatal care and/or during 
the third trimester’.27 Likewise, the United Kingdom Newborn Screening Centre 
provided guidance in 2005 to this effect in their Policies and Standards for Newborn 
Blood Spot Screening in the UK where reference to provision of a pre-screening 
leaflet is made three times under ‘Process Standards’, ‘Consent and Communication’ 
and ‘Blood Sampling Guidelines’.28 One of the earliest references to the suggested 
provision of information about screening in the third trimester was made by the 
United States Task Force on Newborn Screening in 1999.29 New Zealand would 
benefit from a requirement that information about screening be given to parents by 
or in the third trimester and from explicit statement of that requirement in current 
policies and standards, and also in relevant legal documents or arrangements relating 
to the provision of maternity services.30 
.2  right : right to be fully informed
Right 6 of the Code provides consumers with the right to be fully informed. Right 
6(1) states that every consumer has the right to the information that a reasonable 
consumer, in that consumer’s circumstances, would expect to receive. More 
specifically, right 6(1) states that the consumer is entitled to:
(a) an explanation of his or her condition;
(b) an explanation of the options available, including an assessment of the expected 
risks, side effects, benefits, and cost of each option;
(c) advice on the estimated time within which the services will be provided;
(d) notification of any proposed participation in teaching or research, including 
whether the research requires and has received ethical approval;
(e) any other information required by legal, professional, ethical and other relevant 
standards;
(f) the results of tests; and
(g) the results of procedures. 
3.2.1  Right 6 and the context of screening
The language in right 6(1) appears to be drafted with a primary focus on situations 
in which a consumer has presented with symptoms or complications that need 
diagnosis and treatment. Expectations and standards for diagnosis and treatment in 
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the context of clinical services may vary from those in the context of screening. The 
caution voiced by Sandra Coney about the applicability of the Code to the context of 
screening needs to be borne in mind.31 The list in right 6(1) is, however, illustrative 
and not exhaustive, and would thus, where appropriate, allow for adaptation or 
modification to the circumstances demanded by a particular screening programme.
The significance of a ‘screening pathway’ must be appreciated. The Women’s Health 
Action articulated the following in the context of breast and cervical screening in 
July 2000:
There has been a tendency … to inform women just about each step at a time, 
to seek consent only [for] the screening test. Having a smear or a mammogram 
is just one step on the screening pathway. For women who are recalled, there will 
be other decisions to be made. It is a critical part of informed consent for women 
to know about the entire screening pathway and the possible things that might 
occur before they take the first step. This is a complex form of informed consent 
because it requires potential participants to be able to imagine themselves in 
situations that might occur before they are faced with them. This is important 
to prepare women for the possibility of an abnormal result and for recall. In 
research on screening programmes women have consistently said that they want 
more information at the time of the initial screening test about the meaning of an 
abnormal result and what will happen after that. (Emphasis added.)32
In 2003, the National Health Committee (NHC) provided formal guidance emphasising 
that screening is not just about the initial test but also embraces a sequence of events 
that comprises the screening pathway.33 The ‘screening pathway’, which is described 
as the screening process from a participant’s perspective, includes:34
1. an invitation to be screened;
2. being given information about the purpose of the screening, the likelihood and 
possibility of false positive/negative results, the uncertainties and risks attached 
to the screening process, any significant medical, social or financial implications 
of screening for the particular condition or predisposition, follow up plans, 
including availability of counselling and support services;35
3. being questioned or offered a test;
4. having the test;
5. receiving of test results;
6. assessment and diagnosis if the test is positive;
7. possible treatment; and
8. understanding that there are activities to monitor and evaluate all these stages.
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It can be seen therefore that screening involves a number of discrete steps, each of 
which is associated with particular obligations on the part of the provider, actions 
on the part of the consumer, and attention and commitment by both parties to see 
through the whole of the screening process. Each screening programme also has its 
unique aspects with its own target population and particular goals that will need to 
be reflected in the specific details of the screening pathway. 
A set of overseas recommendations may be helpful at this juncture. In 2000, 
the American Academy of Pediatrics (AAP) Task Force on Newborn Screening 
published a ‘blueprint’ for the future of newborn screening to address concerns 
about variability among the newborn screening programmes in the United States, 
and to develop a strategy to resolve ongoing and emerging challenges.36 Several key 
factors for successful screening were identified.37 Most notably, the AAP provided 
seven recommendations regarding what should be present in parents’ educational 
material:38 
1. the benefits of screening;
2. the potential risks of the screening test;
3. how parents will be informed of screening results;
4. the possibility of a false-positive test result;
5. the importance of responding to a positive test result;
6. how to respond to a positive test result; and
7. the screening program’s policy for sample storage and use of stored samples.
The list set out by the NHC and, where appropriate, the AAP recommendations can 
inform the application of right 6(1) in the newborn screening context and should be 
reflected in relevant material and sources, such as the leaflet distributed to parents, the 
National Metabolic Screening Programme (‘NMSP’) website or the interim standards.
Rights 6(1)(a) and (b) are predicated on clinical diagnosis and treatment for which 
the patient or consumer initiates the contact or therapeutic relationship. The NHC’s 
recommended screening process (1), which is expressed in terms of an invitation to 
be screened, should be adopted and made more explicit when approaching potential 
screening participants. Highlighting the invitation for screening would emphasise 
the element of choice, and the voluntary nature of the process, and remove any hint 
of compulsion in relation to participation.
The matters spelt out at length in the NHC’s screening process (2) can be incorporated 
within the scope of right 6(1)(e). This would, among other things, clearly and 
unambiguously emphasise that the purpose of participation in screening is the 
primary interest of the child. The leaflet, as currently worded, seems acceptable and 
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clear, although it could be strengthened with explicit reference to the ‘interest’ of the 
newborn.
3.2.2  Notification of results
Right 6(1)(f) and (g) and the NHC’s screening process (5) raise the issue of 
notification of test results. The newborn screening programme has been operating 
on the basis that ‘no news is good news’ and the practice is presently communicated 
upfront in the leaflet given to parents. Arguably, this would satisfy the AAP’s third 
recommendation regarding the way in which parents will be notified of the screening 
result, and how this procedure is expressed in parents’ educational material (in this 
case, they will not be informed if the test result is negative). The ‘no news is good 
news’ practice has not been unique to New Zealand. However, overseas trends are 
shifting. In the 2005 United Kingdom Policies and Standards document, one of the 
principles under ‘Consent and Communication’ states that:
Parents have a right to information about their baby’s screening result including: 
the reason for any repeat samples; and ‘normal’ as well as ‘abnormal’ screening 
results.39
The Victorian Newborn Screening Review Committee in their report to the Minister 
of Health (August 2006) recommended ‘[t]he development of a result notification 
system for the newborn screening program’.40 Additionally, the Committee’s draft 
model information sheets for presentation to parents when seeking their consent 
provide that:
All parents are notified by mail of their baby’s newborn screening results (if 
normal), or by telephone (if re-testing required).41
Without any New Zealand survey or empirical data available, it is difficult to form a 
view as to whether the ‘no news is good news’ practice should continue or be changed 
so that parents are notified of their newborn screening test results. The Victorian 
Newborn Screening Review Committee recommendation appears to have been 
based on research commissioned by the Health Issues Centre that called for ‘[r]esults 
of the screening to be sent to all parents’ and voiced the principle that ‘[p]arents have 
a right to information about their baby’s screening result’.42 The survey by the Centre 
found that:
A majority of consumers stated they would like to have some confirmation of the 
results sent to them. Several commented that the current practice of ‘if you don’t 
hear anything, it’s OK’ was not adequate.43
For New Zealand, ‘no news is good news’ seems to have been a practice that has 
worked well to date. The practice is less contentious when general awareness and 
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knowledge of newborn screening is low or non-existent. However, if newborn 
screening increasingly operates within a paradigm that more actively promotes the 
exercise of informed choice and consent, ‘no news is good news’ could be regarded as 
falling short of the expectations of parents to be informed throughout the screening 
process, including being notified about the result of the screening test. An argument 
against changing the practice of ‘no news is good news’ is that most results will be 
normal because the disorders for which screening presently takes place are rare. 
Nevertheless, the future may demand a change when complex issues arise with 
technologies that reveal carrier status or if screening is extended to include late-onset 
disorders. It is important for surveys and empirical studies to be undertaken in New 
Zealand to inform policy in this area. Additionally, public discussion needs to take 
place, such as debate by parliamentarians in the chamber after public submissions 
on the issue.
3.2.3  Information about quality assurance activities
Activities to monitor and evaluate newborn screening raise interesting issues relating 
to the right to be fully informed under right 6(1) with regard to the NHC screening 
pathway, and also relating to rights 7(9) and 7(10) which will be discussed at 3.3.4. 
For brevity, activities to monitor and evaluate, as with the activities stated at right 
7(10)(c), will be referred to as ‘quality assurance’ (QA) activities.
Right 6(1) does not explicitly mention QA-related activities but includes reference to 
the right to receive ‘any other information required by legal, professional, ethical, and 
other relevant standards’.44 This allows for the incorporation of the NHC’s screening 
pathway of which an element recommends ‘understanding that there are activities 
to monitor and evaluate’45 from a participant’s perspective. All the other elements 
of the NHC screening pathway – consistent with the detail and intent of right 6(1) 
– promote understanding, communication, choice and ongoing involvement for the 
participant. 
The view that is taken at this point – subject to refinement in the discussion about 
right 6(1) in the context of rights 7(9) and 7(10) – is that activities to monitor 
and evaluate the newborn screening programme need to be more explicitly stated 
in information provided to parents in line with the NHC’s screening process (7) 
and right 6(1).46 Participation in a screening programme encompasses more than 
just the screening test and includes other essential components or activities such as 
monitoring and evaluation.47 Presently, information for parents is provided in the 
leaflet ‘Your Newborn Baby’s Blood Test’ and the NMSP website. The suggestion here 
is that the leaflet should mention that QA-related activities will be undertaken. It 
would also be helpful if the leaflet pointed parents to the website on which more 
detailed information could be provided.
270
3.2.4  ‘Reasonable patient’
Rights 6(1) and 6(2) of the Code provide that the right to be fully informed means 
every consumer has the right to information that ‘a reasonable consumer, in that 
consumer’s circumstances’ would expect to receive, or needs in order to make an 
informed choice or give informed consent. This raises two issues. Firstly, there is 
the issue of the amount of information that should be provided (i.e. ‘how much’ 
information should be provided); this has been discussed above at 3.2.
Secondly, there is the issue of timing (i.e. ‘when’ information should be provided). 
Right 6(2) specifies that the right to information should be implemented just before 
the consumer makes an informed choice or gives informed consent. By comparison, 
right 6(1), which is drafted in more general and open-ended terms, is not limited in that 
way. It has been noted that right 6(1) applies to post-operative communications.48 The 
applicability of the Code to the screening context needs to be kept in mind; therefore 
right 6(1) should be read as applying the standard of disclosure of information at 
every step of the screening pathway from the start to the end and not just in relation 
to the screening test, i.e. the taking of heel-prick blood samples. 
The standard of disclosure of information under right 6 needs to meet the threshold 
required by ‘a reasonable consumer, in that consumer’s circumstances’. It has been 
observed that:
[w]hat information ‘a reasonable consumer, in that consumer’s circumstances’ 
would need or expect calls for a judgment from the provider, and, in determining 
a complaint, the Commissioner. The open-ended nature of this over-arching 
right allows for standards of disclosure to develop over time.49
It can also be added here that the language of the test is drafted broadly enough to 
allow standards of disclosure that accommodate the special features of the newborn 
screening context. These features include, for instance, standards of disclosure that 
take into account every element of the screening pathway as provided in the NHC 
guidance; developments in genetic knowledge and technologies; and the increase in 
the number of disorders being screened. All this can potentially make the obligation to 
meet the standard of disclosure seem quite onerous given that the programme has near 
100 per cent coverage with the parents of over 55,000 newborns being involved.50
However, a couple of factors should be considered. First, the rarity of the disorders 
means that the number of newborns diagnosed and followed up will be small. 
Secondly, the profile of parents involved can be worked out in specific detail well 
in advance and within a limited number of discrete categories, such as first-time 
parents, second-time parents etc. (A note of caution should be sounded here against 
the making of assumptions that second-time parents will have good familiarity 
and recollection of newborn screening information previously provided when they 
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had their first newborn.) Additionally, these two factors, considered together, may 
help inform thinking about how the standard for information disclosure relating 
to newborn screening can be satisfied, and also about attitudes and expectations of 
parents regarding information on participation in newborn screening.
3.2.5  Aims of the newborn metabolic screening programme
The discussion has focused so far on the rights contained in the Code in the context 
of the NHC’s screening pathway, from a participant’s perspective. The pathway 
begins with the recommendation for an invitation to be screened, includes the test 
itself, and ends with the participant’s understanding there are activities to monitor 
and evaluate at all stages. Each of these stages contributes to the fulfilling of the aims 
of the newborn metabolic screening programme, which are:51
1. to enable early detection of pre-symptomatic newborns;
2. to ensure appropriate early treatment of newborns;
3. to ensure newborns born with congenital metabolic disorders have their 
development potential impacted as little as possible from the disease;
4. to inform the community of all aspects of newborn screening including 
advantages and outcomes;
5. to facilitate early diagnosis, appropriate treatment and continuous monitoring 
of specific metabolic diseases;
6. to facilitate continuous quality improvement through the development of a 
quality assurance, reporting and strategic planning framework;
7. to provide educational resources to programme participants.
In the context of dried blood spots collected for the screening programme, there have 
been specific instances in which they have been released for purposes not related to 
the fulfilling of the aims of the programme. For example, in H v G the Court ordered 
release of dried blood spots relating to a deceased child for the purpose of proving 
paternity in a civil suit. Samples have also been released for use in the criminal context 
to match biological material found at a crime scene in order to identify victims.
As for the use of dried blood spots for the purposes of health research, the NTC 
Director has said that no research has occurred on stored de-identified dried blood 
spots in New Zealand.52 However, even if the use of dried blood spots in health 
research may not be regarded as fulfilling the aims of the programme, some research 
proposals that involve the use of dried blood spots may inform or indirectly relate to 
the aims of the screening programme. Looking to the future, the potential benefits 
from the use of dried blood spots for research that yields generalisable knowledge 
will be significant in advancing many areas of health, from knowledge of clinical 
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genetics to population-based initiatives in public health. It is the view of the authors 
of this report that health research involving the use of de-identified dried blood 
spots collected for newborn screening should be encouraged as a matter of principle. 
In practice, research proposals must be carefully scrutinised on their merits and 
prioritised, given that the remaining dried blood spot samples are finite.
The past instances in which dried blood spots have been released for purposes not 
related to fulfilling the aims of the programme, and the potential benefits of using 
them for the purposes of health research that may inform or indirectly relate to 
improving the programme, bring home two points. First, it is important to distinguish 
between purposes that fulfil the aims of the programme and those that go beyond 
the aims of the programme. Secondly, there has to be clear policy for the retention 
and use of the dried blood spot samples that conveys that distinction. The right to be 
fully informed, pursuant to right 6, means that information about retention and use 
of dried blood spots, relating to purposes that fulfil the aims of the programme and 
purposes that go beyond the aims of the programme, must be given to participants 
so that they can exercise informed choice and consent. The issue of timing, and the 
amount of information to be given, is crucial.
.  right 7: right to make informed choice and give informed consent
3.3.1  Right 7 and the context of screening
The Code of Rights, as provided in right 7(1), brings legal force to the ethical 
requirement for informed choice and informed consent where a health-care 
procedure is not required by law.53 Right 7(1) provides that:
Services may be provided to a consumer only if that consumer makes an informed 
choice and gives informed consent, except where any enactment, or the common 
law, or any other provision of this Code provides otherwise.
Even though it is qualified by a standard drafting phrase that allows for exceptions, 
right 7(1) is written in strong, unambiguous language that communicates clear intent 
for general application. The definition of ‘services’ includes health-care procedures 
and ‘consumer’ includes a person entitled to give consent on behalf of a consumer.54 
‘Services’ is a term wide enough to encompass the newborn metabolic screening 
programme, and the taking of heel-prick blood samples for newborn screening 
comes within the word ‘procedure’. In the case of newborn screening, the newborn is 
the consumer on whose behalf parents or legal guardians can lawfully give consent 
for participation. As has been noted, the right of the consumer to make informed 
choice and give informed consent applies in relation to the whole screening pathway 
if the aims of the screening programme are to be fulfilled.
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The Health and Disability Commissioner, in his opinion on Case 99HDC09011, 
said health-care professionals ‘should not undertake the Guthrie Testing procedure 
without ensuring that informed consent has been obtained’.55 The Commissioner 
also called for a policy to ensure that informed consent is obtained from parents 
or legal guardians.56 Presently, an explicit policy to that effect does not appear to be 
publicly available although it seems conceivable that the policy will be contained in 
or will underpin the documents that are signalled as being in the planning stages, e.g. 
‘Quality and policy standards’ and ‘Storage, retention and use of blood spot cards’.57 
In place of the former are interim standards that exist but are not yet posted on the 
NMSP website.58 
The Ministry of Health, in the document Improving quality: A framework for screening 
programmes in New Zealand, pointed out a number of matters that are relevant here. 
Principle 6 emphasises that:
Obtaining informed consent from eligible individuals is paramount. This includes 
the right to make an informed choice not to participate in screening, based on 
sound information.59
To encourage principle 6 to be put into action, so as to deliver on a ‘screening 
programme quality agenda’,60 the Ministry of Health has given guidance in the 
form of a checklist of expectations of provider responsibilities for implementation 
at various levels (i.e. at the level of the individual, team and organisation) which 
provides that:61 
• the individual (health professional) is responsible for ‘obtaining informed 
consent from people participating in the programme after discussing both the 
benefits and limitations of screening’;
• the team (of providers) is responsible for ‘ensuring that individuals within the 
team are supported to obtain informed consent’; and
• the organisation is responsible for ‘ensuring that individuals have the time 
to obtain informed consent and provide necessary explanations to people 
participating in the programme’.
We suggest that principle 6 and the guidance provided be clearly incorporated into 
the interim standards if this has not already been done.
With regard to the right to exercise informed choice and consent in the context of the 
Code, the specific provisions of rights 7(9) and 7(10) are of particular significance and 
require careful consideration. The recent amendment to right 7(10) makes explicit and 
emphatic reference to issues regarding monitoring and evaluation for the first time in 
the Code. Closer examination of the issues relating to practice, implementation and 
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operation reveals that the interpretation of right 7(10) demands careful thought in 
relation to right 6(1), which promotes the right to full information, and right 7(9), 
which deals with return or disposal of bodily material. The discussion that follows 
contains some comment about retention or storage of dried blood spots, for fulfilling 
the aims of the newborn screening programme, and QA for newborn screening and 
an examination of the inter-relationship between rights 6(1), 7(9) and 7(10).
3.3.2  Retention of dried blood spots and physical or ‘scientific’ limitations on storage
The current practice of the National Testing Centre is to store the blood spot cards 
indefinitely after the tests for the seven disorders have been completed. The National 
Testing Centre has been storing blood spot cards (‘Guthrie cards’) for thirty-four 
years.62 It is estimated that it currently holds more than two million samples, from 
both living and deceased New Zealanders.63 
The utility of these blood samples is heavily dependent on the state of the technology. 
Twenty years ago, information that could be garnered from these samples was not of 
such great consequence. The utility of the samples was confined to the purpose of 
the newborn screening programme. With the advent of DNA technologies, including 
DNA profiling,64 and the completion of the Human Genome Project, the degree 
and scope of information that can be derived from retained dried blood spots can 
potentially be very significant and have far-reaching implications.
In the report commissioned by the Health Resources and Services Administration, 
U.S. Department of Health and Human Services for public comment, entitled 
Newborn Screening: Toward a Uniform Screening Panel and System, it was stated, in 
the section discussing ‘Establishing Principles for the Development of Newborn 
Screening Guidelines’, that:65
Newborn screening specimens are valuable health resources. Every program 
should have policies in place to ensure confidential storage and appropriate 
use of specimens.
Specimens obtained for newborn screening have tremendous long-term value. 
They can be used for purposes of program quality management, to help 
inform deliberations about program expansion, and for research on testing 
technology and treatment and for epidemiologic studies. This is not to imply 
that every State should store all specimens forever but, rather, that there should 
be sufficient member States with diverse populations and long term storage of 
residual specimens to provide this critical resource. Regardless, it is important to 
ensure the confidentiality of those persons whose specimens are stored. The use 
of specimens for non-therapeutic purposes must not alter the willingness of the 
public to participate in newborn screening programs and related activities.
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A complete DNA profile of an individual can be obtained from the blood spots on 
the cards.66 DNA profiles can be used to match DNA samples, from blood, tissue and 
other specimens, to individuals. The blood spot cards can also be used to identify 
genetic defects that lead to early and late-onset diseases in individuals. The cards 
may also provide information on a person’s susceptibility to other diseases and 
disorders. These advances in technology mean that the blood spot cards can be used 
for purposes beyond which the samples were originally taken; that is, screening for 
metabolic disorders. The Australian Law Reform Commission found that:
Developments in genetic technology have made it possible to perform almost all 
available genetic tests on stored tissue, provided it has been adequately preserved. 
Large amounts of potentially sensitive information about the person from whom 
the tissue was taken and his or her family can be obtained from archived tissue. 67
New Zealand’s own Privacy Commissioner has commented that privacy concerns in 
relation to stored blood spots are heightened by the developing range of information 
which can be obtained by the analysis of old blood samples and the decreasing cost 
of carrying out such analysis.68
Worldwide, blood spot cards are now used for a variety of purposes, many of which 
go beyond the ambit of newborn screening programmes:
• investigation of cases missed by the screening programme (confirmatory 
diagnosis of false negatives);69
• screening programme development, method development and establishing 
normal ranges for new and existing tests (evaluation of new and existing tests);
• requests from health professionals for the purpose of clinical investigation;70
• coronial and forensic purposes;71
• research purposes, including:
 - epidemiologic surveys of infectious diseases72
 - population-based studies of environmental and pharmacologic exposures73
 - etiologic studies of birth defects and developmental disabilities74
 - population-based studies of haplotype and allele frequencies for genetic   
 disorders and potentially significant gene polymorphisms.75
In New Zealand, the purposes of storage appear at first glance to be limited. The 
leaflet issued by the Newborn Metabolic Screening Programme states that:
When the testing of your baby’s blood is completed, the sample card is stored so that 
if a baby has one of the conditions tested for, but does not have a positive test result 
we can find out why the mistake occurred again. Some of the blood might be used to 
set up new screening tests; if a leftover scrap of your baby’s blood is used for this all 
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the information about your baby will be disconnected from the blood so any results 
cannot be traced back to you and your baby.
This conveys that there is a dual purpose in the storing of blood spot cards. First, they 
are stored to allow investigation of instances in which a baby, who has been screened 
and tested negative, develops one of the conditions for which the baby has already 
been screened. Some of the conditions tested for do have the potential to present as 
late-onset disorders, e.g. in adulthood. Other disorders may have milder forms that 
are not detected by initial newborn screening. The leaflet provides little indication as 
to how long samples are needed for this purpose. The second stated purpose is for the 
setting up of new screening tests. In connection with this purpose, the leaflet does not 
provide any indication as to the degree of identifiability of the stored sample cards, 
e.g. whether use of the cards for this purpose will be in de-identified, identifiable or 
anonymised form.
The use of blood spot samples stored on filter paper is subject to two physical or 
‘scientific’ limitations. The first relates to the actual physical size or amount of the 
blood spot samples. The second relates to the stability of the analytes present in the 
blood spots.76 The stability of the analytes, and the amount available for testing, 
limits any proposed future use of the blood spot samples.
The first limitation relates to the amount of blood initially taken and eventually stored. 
When samples are taken, the blood is spotted onto four rings marked on filter paper.
Holes are punched from the four dried blood spots for the purposes of newborn 
metabolic screening. The amount used during the testing process can range from 
one blood spot sample (that is, one ring) to all of the blood spot samples.77 In some 
instances, more blood may be required from the newborn to complete testing, such 
as when initial samples are inadequate, or it is necessary to follow up investigation 
of false negatives.
Metabolites initially tested during the newborn screening process have a finite life 
span.78 At some point these metabolites become unstable or are degraded in such a 
way as to no longer produce meaningful test results (or, in some instances, any results 
at all). Storage conditions are known to affect the stability of metabolites. The Council 
of Regional Networks for Genetic Services concluded that maximum stability could 
be achieved for most analytes when samples are stored at low temperature and in 
controlled low humidity.79 The Council also noted that its search of scientific literature 
on the stability of analytes in dried blood spots was of minimal value; there was a 
lack of published data that would allow meaningful conclusions about long-term 
storage to be drawn.80 The Australian Law Reform Commission has commented that 
proper long-term storage of newborn screening cards for research purposes would 
be complex and expensive.81 Given these observations, it is important to appreciate 
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that the stability of metabolites in dried blood spots is not infinite; at varying times 
metabolites will lose their ability to produce meaningful results. Storage conditions 
can enhance the length of time for which metabolites will be stable, but they cannot 
do so indefinitely.
One substance in dried blood spots is known to persist longer than any other 
metabolite – deoxyribose nucleic acid (DNA).82 In 2005, Chaisomchit et al. concluded 
that genomic DNA is stable in dried blood, stored on filter paper at ambient tropical 
conditions, for at least eleven years. However, it was found that DNA quality for 
amplification of larger DNA fragments decreased when the specimens were stored 
for longer than ten years.83 The authors of the study noted that no other published 
data exist regarding the effects of long-term storage of dried blood specimens on the 
stability of genomic DNA.84 The New Zealand case involving criminal investigations 
into the suspected murder of Olivia Hope and identification of hair and blood 
samples suggests that DNA is viable for analysis for up to twenty-one years.85 In that 
case, DNA analysis was carried out on dried blood spots, that had been collected for 
newborn screening, with the purpose of comparing and identifying DNA extracted 
from hair and blood samples found at the alleged crime scene.86
The physical or ‘scientific’ limitations must be borne in mind when considering any 
policy development in relation to the retention and long-term storage of newborn 
blood spot cards. Current and relevant scientific literature on the stability of 
metabolites, DNA extraction and testing technology and optimal storage conditions 
needs to be taken into account in any policy development in this area. 
3.3.3  Right 7(10) and quality assurance activities
Right 7(10) of the Code states that ‘no body part or bodily substance removed or 
obtained in the course of a health-care procedure may be stored, preserved or used 
otherwise than … with the informed consent of the consumer’.87 One of the exceptions 
to this is provided ‘for the purposes of a professionally recognised quality assurance 
programme, an external audit of services, or an external evaluation of services’ where 
these activities are ‘undertaken to assure or improve the quality of services’.88
In Screening to improve the health of New Zealand: Criteria to assess screening 
programmes, the National Health Committee defines ‘quality’ as embracing the 
following concepts:89
• Safety – the extent to which harm from a service is kept to a minimum;
• Consumer focus – the extent to which a service meets the needs of consumers, 
incorporates community values and allows opportunities for participation and 
input into decision-making;
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• Access – the extent to which people are able to receive a service on the basis of 
need and irrespective of factors such as ethnicity, age, location, impairment or 
gender;
• Effectiveness – the extent to which a service achieves an expected and 
measurable benefit;
• Efficiency – the extent to which a service obtains the greatest possible benefit 
from available funding, i.e. value for money.
The National Health Committee has also noted that:90
Poor screening programme quality, or a decline in screening programme quality 
can tip the balance between benefits and harms the wrong way. Once the 
invitation to be screened is issued, there is an ethical obligation to ensure that 
the programme can deliver the potential benefits through appropriate quality 
management. It often requires significant investment to achieve and maintain 
the level of quality necessary to ensure the expected benefits occur.
The Health and Disability Commissioner has commented that:91
consent to the provision of a health service implies consent to proper audit and 
evaluation of the service. The public assumes that medical laboratories have QA 
procedures in place to check that specimens have been read correctly.
The three activities afforded exemption under right 7(10)(c) – i.e. ‘quality assurance’, 
‘external audit’ and ‘external evaluation’ – are aimed at ensuring screening programme 
quality. Some definitions may be helpful in order to shed light on these expressions, 
which may seem like terms of art, specific to a certain profession or group of experts. 
We searched for relevant comments or guidance on these expressions in the screening 
context.
‘Quality assurance’ has been defined by the NHC as the ‘detection of problems 
through external or internal inspection, and their correction through systematic 
activity’.92 By implication, the Privacy Commissioner seemed to suggest that, for the 
newborn metabolic screening programme, a formal audit process would involve going 
back to a representative sample of the cards and retesting the samples.93 An ‘external 
evaluation’ has been described by the National Screening Unit (NSU) as ‘monitoring 
and assessing the service delivery and outcomes of a screening programme, which 
may include assessing overall programme effectiveness, cost-effectiveness and 
acceptability’. The NSU also noted that an ‘evaluation will determine whether the 
programme is actually delivering on its objectives’.94 
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In 2003, the Privacy Commissioner observed that:95
The National Testing Centre considers that its handling procedures, rather than 
any questions of ‘reading’ or evaluating samples or test results, are what matters 
in terms of quality assurance. The Centre undergoes regular accreditation audits. 
These do not involve subsequent re-testing of samples or their retention for that 
purpose.96
The Health and Disability Commissioner’s complaint investigation in Case 
99HDC09011 was provided with the following information:
Where there is a mistake made in the testing of the sample and a case of one of 
the screened conditions is missed … the original sample would be sent to another 
newborn screening laboratory for checking on different equipment. This is a 
crosscheck on the sample and also useful from quality assurance perspective.
The investigation of cases missed by a screening programme has been noted as the 
primary purpose of retention of screening samples in the HGSA’s Policy statement on 
the retention, storage and use of sample cards from newborn screening programs.97 The 
newborn screening programme undergoes peer review every two to three years and 
internal audits are carried out annually.98
Our search for information in this area reveals that New Zealand participates in an 
organised QA programme; one in which more than fifty other countries participate. 
The Newborn Screening Quality Assurance Programme (NSQAP) is run by the 
Centres for Disease Control and Prevention and the Association of Public Health 
Laboratories. The programme has two core components designed to ensure the 
quality of newborn screening programmes: quality control and proficiency testing.
The quality control component involves distribution of dried blood spot materials at 
six-monthly intervals by the NSQAP. Participating laboratories are expected to return 
quantitative results from five different analytical runs, having utilised the dried blood 
spot materials supplied. The NSQAP compiles and distributes the reported results. 
Laboratories can compare their results with those obtained by other laboratories in 
order to gauge the accuracy of their quantitative results. 
Proficiency testing involves the distribution of quarterly panels of dried blood spots 
that participants are expected to analyse once. Participants are expected to return 
analytical results and qualitative (clinical) assessments. These results and assessments 
are performance graded by the NSQAP. As with the quality control programme, 
the NSQAP compiles and distributes proficiency testing reports. These reports 
show the distribution of analytical values and qualitative assessments reported by 
participants.
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Involvement in this QA programme would come within the definition of a 
‘professionally recognised quality assurance programme’ under right 7(10)(c)(i). 
Hence, storage for such purposes without the informed consent of the consumer 
may not result in a breach of the Code of Rights, as might have been the case before 
the 2004 amendments to right 7(10).
3.3.4  Inter-relationship of right 7(10), right 6(1), right 7(9) and the National Health   
 Committee (NHC) screening guidance, and options for reconciling them
Prior to the amendment of right 7(10), the consumer’s informed consent was 
necessary for the storage, preservation or use of any body parts or bodily substances 
removed or obtained during the course of a health-care procedure. Recent changes 
to right 7(10) removed the need to obtain informed consent for QA activities, i.e. 
‘activities that are … undertaken to assure or improve the quality of services’, such 
as professionally recognised QA programmes, external audits of services or external 
evaluations of services.99
A plain reading of right 7(10) by itself may give cause for concern that QA activities 
can (and, as they are essential steps in the screening pathway, will) inevitably take 
place and involve the use of a consumer’s bodily material regardless of that consumer’s 
knowledge or continuing support for or involvement with the health service at 
issue. The Health and Disability Commissioner has responded to concerns over the 
implications of the new right 7(10) by saying that it applies in limited circumstances 
and safeguards exist in the Code and Ethics Committee review.100 The Health and 
Disability Commissioner has also pointed out that right 7(9) continues to be available 
for consumers who require the destruction or disposal of their bodily material.101
A few observations can be made about the relationship between the amended right 
7(10) on the one hand, and right 7(9), right 6 and the NHC guidance regarding the 
screening pathway on the other. By implication, the exception created by the newly 
amended right 7(10) seems to limit or restrict the full extent of the operation of the 
right to be fully informed as provided by right 6. Secondly, even though the recent 
changes to right 7(10) may seem supportive of one of the elements of the NHC’s 
screening pathway, by enhancing the participant’s understanding of the fact that 
there are activities to monitor and evaluate at every stage of the screening process, 
right 7(10) does not seem to be in keeping with the spirit of the NHC’s screening 
pathway as a whole in terms of encouraging ongoing engagement with screening 
participants. Thirdly, QA activities can be conducted under right 7(10) without 
informed consent only so long as right 7(9) is not exercised by consumers to require 
the return or destruction of their bodily material.
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The question that arises here is:102 How can the consumer’s right to require the 
return or disposal of bodily material103 and, more generally, the right to be fully 
informed,104 and the NHC screening guidance for informed choice and consent 
and understanding about QA activities,105 sit consistently alongside the exception 
in right 7(10) that allows QA activities to be undertaken on bodily material without 
informed consent?
 right or guiDance relationshiP    
Right 6 provides the right for  Not consistent with right 7(10)(c) 
consumers to be fully informed but consistent with NHC guidance
The NHC screening pathway 
includes elements that promote:
• informed choice and informed Not consistent with right 7(10)(c) 
 consent (elements of pathway, but consistent with right 6 
 taken as a whole) 
• understanding of the fact that Not consistent with right 6
 there are activities to monitor  but consistent with right 7(10) 
 and evaluate at all stages of the 
 pathway (last element of pathway) 
Right 7(10) precludes the obligation Not consistent with right 6 
to obtain informed consent to store, 
preserve, or use bodily material for 
QA purposes
Right 7(9) provides the right for Not consistent with right 7(10)(c)   
consumers to require the return but consistent with NHC guidance  
or disposal of their bodily material
Table 1: Inter-relationship of rights 6(1), 7(9), 7(10) and NHC screening guidance
After examining the underlying tensions arising from right 7(10), right 7(9), right 
6 and the NHC guidance, and reflecting on how they can be reconciled in practice 
with minimal conflict to achieve the best possible result, we propose the following 
two options.
Option A: Status quo with active communication of more information about right 7(9) 
and right 7(10)
Option A involves opting for the status quo with retention of the dried blood spot 
samples indefinitely and with the programme being subject to the general operation 
of the law. However, to give greater effect to the Code and enhance awareness of 
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the rights therein, so that they can be meaningfully exercised, two things have to 
be actively done. First, parents need to be told about the use of samples without 
informed consent for the purposes of QA-related activities as consistent with right 
7(10)(c). Secondly, at the same time, parents also need to be told that they have 
the right to ask for return or disposal of their newborn’s dried blood spot sample, 
consistent with right 7(9).
Given the underlying tension between right 7(10)(c) and right 7(9) in practical 
operation, we suggest that communication of both these rights be accompanied by 
reassurances about safeguards relating to use of the samples for QA-related activities, 
and strong encouragement regarding participation in the programme for the benefit of 
the newborn. A specific example of this is to tell parents that samples will, for practical 
purposes, need to be retained for a particular period of time for QA-related activities 
to be carried out and that the exercise of right 7(9) before or during that period will 
prevent this from happening. A specific, designated time period will go some way 
towards providing parents with a timeframe during which to defer the exercise of right 
7(9). It would be helpful for this information to be included in the leaflet distributed 
to parents and posted on the NMSP website, and also for the Interim Standards to 
include guidance for LMCs to convey the information to parents.
There appear to be good arguments in favour of the status quo, strengthened by the 
suggestion of conveying reassurances and encouragement to parents and, incidentally, 
the wider public. Until now, there seems to be no overt, publicly documented concern 
or objection regarding the way in which things are working. It would be reasonable 
to continue with the status quo until such time as current arrangements should be 
reviewed, such as when significant numbers of samples were needing to be returned 
or destroyed so that QA-related activities could not be undertaken in a statistically 
meaningful way. This option is effectively underpinned by the policy to persuade 
parents themselves to waive their exercise of right 7(9) for a specified period.
Option B: Legal authority to prescribe a minimum retention period to guarantee all 
samples are available for QA-related activities
Option B involves prescribing a minimum period during which the programme can 
retain dried blood spot samples so that all the samples are available for QA-related 
activities, hence enabling the screening pathway to be completed. However, as it is 
open for parents to exercise the right for disposal or return of the samples at any time, 
legal authority (i.e. in the form of statutory authority) will be needed to override the 
ability to exercise right 7(9) for a specified period in order to guarantee availability 
of all samples for QA-related activities. Another way of characterising this is that 
legal authority would be needed for temporary, time-limited suspension of right 7(9) 
while QA-related activities on all samples could be carried out unhindered.
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With this option, at least two things should be done in order to strengthen current 
arrangements relating to the voluntary system of newborn screening in New 
Zealand. First, parents need to be told explicitly about the statutory authority that 
– for a temporary, time-limited period – overrides or suspends their right to ask 
for disposal or return of the samples. Secondly, to preserve the participation rate in 
the programme of, to date, almost 100 per cent of newborns, the message should be 
communicated to parents that QA is a key component of the screening programme.
Several matters can be noted regarding this option (Option B) that require additional 
consideration. The first is the question of the implication on the future participation 
rate for the screening programme. Presently, no relevant studies are available from 
which any observations can be made; any comments that can be made would be 
speculative. Hence, research or surveys must be undertaken to ascertain parental 
attitudes in relation to this option so as to inform policy-makers and decision-makers 
before its adoption.
Secondly, there is the question of exactly when samples can be returned or destroyed. 
It is important to emphasise that, as this option involves temporarily overriding or 
suspending the exercise of right 7(9), the specified minimum period for retention 
of samples must be explicitly stated in years, and set out clearly and emphatically in 
information given to parents. Thirdly, to earn support for this option and at the same 
time avoid or minimise the likelihood of drop-out rates in participation for newborn 
screening due to misunderstanding, poor awareness or knowledge or groundless 
fears, clear and unambiguous information that explains and justifies what is being 
done – including information about the specified minimum sample retention period 
as previously discussed– should be provided to parents in the leaflet, for example, 
and on the programme website, and also noted in the Interim Standards.106
These two options, which are not necessarily the only solutions, illustrate the 
range of possibilities – from continuing with the status quo to prescribing specific 
requirements with the authority of the law. It is vital, and to be seen overtly, to take 
policy or legislative steps to reconcile the tensions underpinning the way in which 
right 7(10), right 7(9), right 6 and the NHC guidance relate to each other. It should 
be noted that the discussion has so far focused only on the scope of activities related 
to fulfilling the aims of the newborn screening programme. Issues regarding the 
extent or limits of storage and use of dried blood spots for purposes beyond the aims 
of the programme will be examined later, after brief reference to documentation 
regarding informed choice and consent and refusal of services and withdrawal of 
consent under right 7(1) and right 7(7) respectively.
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3.3.5  Documentation in the context of right 7
The Code, framed in the language of claim rights, is written from the consumer’s 
perspective. Documentation of actions taken, and the administrative systems relating 
to the obtaining of informed consent, the various stages of the screening pathway and 
the screening programme generally, is a matter that rests with the providers or health-
care professionals involved. The Code makes no explicit reference to or requirement 
regarding documentation. Nevertheless, the Ministry of Health, in Improving quality: 
A framework for screening programmes in New Zealand, has stated that ‘[i]nformed 
consent should be documented’.107
In his comments on Case 97HDC8205,108 the Health and Disability Commissioner 
repeated his predecessor’s recommendation for ‘an integrated documentation system 
where records were comprehensive, appropriate, and available to all staff ’ and said he 
‘cannot emphasise enough the importance of integrated documentation systems’.109 
More generally, the Commissioner noted past investigations, which had found patient 
notes had been fragmented and held in a number of places or in the same location on 
a number of forms, and pointed out that this means 
that those who are involved in providing care to the consumer may lack access 
to crucial information at important times, or are unable to refer to the necessary 
information because they cannot find it amongst a myriad of forms. This results 
in confusion for all involved in the consumer’s care, and sometimes in crucial 
information being overlooked by staff, with significant consequences [for] the 
consumer.110
The Commissioner, in Case 97HDC8205, found that the fragmented documentation 
system and poorly co-ordinated service provision failed to ensure quality and 
continuity of care and that the providers and professionals involved were in breach 
of rights 4(5) and 4(2).
In Case 99HDC09011, where the complaint related to informed consent for blood 
samples obtained in relation to newborn screening, the Health and Disability 
Commissioner recommended that LMCs document the fact of disclosure of 
information, the giving or refusal of consent from parents to the taking of newborn 
blood samples and the outcome regarding storage or disposal of those samples.111
The importance of documentation was recently stressed by the Victorian Newborn 
Screening Review Committee, which stated that:
There should be documentation in the mother’s/baby’s hospital record stating that 
there has been discussion about the newborn screening test. The hospital record 
should also show a record of completion of testing. … Any parents refusing testing 
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are requested to sign a written statement saying that they understand the potential 
risks to the healthy development of their baby.
Documentation for retention, release and use of blood spot sample cards is 
recommended in the Policy statement on the retention, storage and use of sample 
cards from newborn screening programs developed by a joint subcommittee of the 
Human Genetics Society of Australasia and the Division of Paediatrics of the Royal 
Australasian College of Physicians:112 
3.2  Retention of sample cards: The screening program should document how  
  long it will retain their cards, including the purposes for retention.
  …
2.2  Release of sample cards: All releases of residual samples should be   
  documented. Such records should include the purpose of release, what   
  material was released, by whom it was used, and the authority for use.
  …
4.3  Uses of sample cards: Specific uses include, but are not limited to,   
  the following. Each program policy should state what permission and   
  documentation are required in each situation:
 4.3.1 Investigation of cases missed by the screening program …
 4.3.2 Screening program development, method development, and   
   establishing normal ranges for new or existing tests …
 4.3.3 Individual requests (i.e. requests for cards to be returned to the   
   family)  …
 4.3.4 Requests from Health Professionals …
 4.3.5 Research Studies …
 4.3.6 Coronial and forensic use … .
In New Zealand, the right of every consumer to refuse services and withdraw consent 
to services is provided by right 7(7), which is the mirror opposite of right 7(1) stating 
that services may be provided only if the consumer exercises informed choice and 
consent. Documentation that records the refusal or withdrawal of consent should 
also record instances in which consent is given. There is guidance in New Zealand 
for implementing provider responsibilities at various levels in relation to obtaining 
informed consent for screening programmes in general (as discussed earlier). 
Specific policies or procedures setting out the requirements for documentation of 
informed consent, or refusal or withdrawal of services, in the newborn screening 
context should be made explicit and publicly available.113 This would help increase 
parental and public awareness, understanding and confidence. The United Kingdom 
2
Newborn Screening Programme Centre provides precedence for material containing 
such policies and procedures to be posted on the internet.114
  FinDings
The analysis in this part of the report is grounded in the rights-based Code of Rights, 
and takes into account the public health paradigm and the striking aspects of dealing 
with genetic risks in families. In this context, it is important to distinguish public 
health screening from personal clinical services. Traditionally, public health law 
has been prescriptive in form and has compelled participation. This is in contrast 
with the increasingly adopted consumer-based approach that promotes informed 
choice and consent and which is in keeping with the complexities and sensitivities 
surrounding genetic medicine.
Information about newborn screening should be given to parents by or during the 
third trimester, and again before the samples are taken. The applicability of the 
Code in the context of screening needs to be borne in mind. The significance of the 
‘screening pathway’ needs to be appreciated: ‘It is a critical part of informed consent … 
to know about the entire screening pathway and the possible things that might occur 
before [taking] the first step’. Clear, unambiguous information needs to be provided, 
emphasising that the purpose of ‘participation’ is in the interests of the newborn.
If newborn screening increasingly operates in a paradigm that actively promotes 
informed choice and consent, parents or guardians will need to be informed 
throughout the screening process; this includes being notified about results. The 
policy of ‘no news is good news’ may have to be reconsidered in the light of complex 
issues raised by technologies that reveal carrier status, or if screening is extended to 
include late-onset disorders. Surveys and empirical studies should be undertaken in 
New Zealand to inform policy in this and other areas. Public discussion, e.g. led by 
parliamentarians, needs to take place.
Activities to monitor and evaluate the programme need to be more explicitly stated 
in information given to parents. Related to this, is the importance of distinguishing 
between initiatives taken for the purposes of fulfilling the aims of the programme and 
those that go beyond aims of the programme. Policies regarding retention and use 
of samples that clearly make and communicate that distinction need to be provided, 
especially to parents.
The utility of the retained blood samples is heavily dependent on the state of the 
technology. With DNA technologies and profiling, the degree and scope of information 
that can be derived from dried blood spots will potentially be very significant and 
have far-reaching implications. There is tremendous long-term value in retention, for 
example, for the purposes of quality management, programme expansion, research 
27
on testing and treatment and epidemiologic studies. Current and relevant scientific 
literature on the stability of metabolites, DNA extraction and testing technology and 
optimal storage conditions needs to be taken into account with regard to any policy 
development in this area. 
Two options are provided in order to reconcile the inter-relationships between the 
various provisions of the Code of Rights on consent, storage and quality assurance 
and the NHC screening guidance: to maintain the status quo by more actively 
communicating information about right 7(9) and right 7(10); or to prescribe, with 
legal authority, a minimum retention period to guarantee all samples are available 
for QA-related activities.
The public availability of policies and procedures setting out, for example, the taking 
and documenting of informed consent would be helpful, in order to increase parental 
and public awareness, understanding and confidence.
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